Jensen J, et al. - In two specialized diabetes clinics in Denmark—the Center for Diabetes research (CfD) at Herlev-Gentofte University Hospital and the Steno Diabetes Center Copenhagen (SDCC) as part of the Thousand&2 Study—researchers assessed heart failure (HF) prevalence and evaluated the diagnostic value of mid-regional pro-atrial natriuretic peptide (MR-proANP) in outpatients. They found that the prevalence of HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) was 2.4% and 17.5%, respectively. Among outpatients with type 2 diabetes, HFrEF was rare. In patients reporting dyspnea, MR-proANP ruled out HFrEF and provided independent information relevant to HF diagnosis.